期刊文献+

齐多夫定生产中叠氮化工艺优化

Zidovudine Azide in Production Process Optimization
下载PDF
导出
摘要 齐多夫定是重要的抗艾滋病毒药物,也是目前抗艾滋病药物中最基本的组合成分。现有合成方法存在原料来源及成本等问题,研究及改进其合成中的工艺具有重要的经济效益和社会效益。本文分析齐多夫定氧桥工艺的优化到叠氮化物结晶工艺的优化。用车间叠氮甲苯液拉干后得到齐多夫定叠氮化物结晶固体,最终异丙醇和丙酮的方案得到的产品纯度高,溶残合格,但产率较低,耗时太长;甲醇和水的方案得到的产品纯度达97.1%,粗品有45.2 g,但是最后的溶残中甲苯含量过高,不适用于生产;而异丙醇和甲醇方案得到的产品产率较高,溶残合格,但纯度较低。 Zidovudine is important anti-hiv drugs, is currently the most basic composition of anti-aids drugs. The existing problems and the cost of raw material source synthesis method, research and improve its synthesis process has important economic and social benefits. This article from the zidovudine oxygen bridge process optimization to azide crystallization process optimization in his writing. With workshop azide toluene liquid, dry after get zidovudine azide crystalline solid, isopropyl alcohol and acetone solution to get the final product high purity, but the yield is low, dissolve the residual qualified, but time is too long; Methanol and water solution to get the product purity was 97.1%, and the crude product is 45.2 g, but the final solution of residual toluene content is too high, do not apply to the production. And isopropyl alcohol and methanol solution of product yield is higher, but lower purity, finally.
出处 《中国资源综合利用》 2017年第3期11-17,共7页 China Resources Comprehensive Utilization
关键词 齐多夫定 氧桥工艺 叠氮结晶 Zidorfset oxygen bridge process stack nitrogen crystallization
  • 相关文献

参考文献7

二级参考文献71

  • 1邱蔚然,唐孝宣,沈荣坤.酶法生产三氮唑核苷的进展[J].中国生化药物杂志,1995,16(2):87-90. 被引量:8
  • 2王鲁平,朱永珙.齐多夫定对获得性免疫缺陷综合征的治疗作用和不良反应[J].新药与临床,1996,15(1):38-40. 被引量:9
  • 3陈发普,余宏宇,李云华,陈发凯,吴秋业.齐多夫定的合成[J].中国医药工业杂志,1996,27(11):483-485. 被引量:8
  • 4沈荣坤,邱蔚然,孙南翔.应用大肠杆菌的核苷磷酸化酶合成胸苷[J].华东理工大学学报(自然科学版),1996,22(6):701-706. 被引量:10
  • 5左淑芳,杨凤艳.抗真菌药萘替芬的合成[J].中国医药工业杂志,1997,28(1):8-9. 被引量:8
  • 6Lin T S,J Med Chem,1978年,21卷,1期,109页
  • 7Yu H, Kalyan D, Ding JP, et al. Structures of tyr188leu mutant and wild-type HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor HBY 097:inhibitor flexibility is a useful design feature for reducing drug resistance [J]. J Mol Biol, 199
  • 8Parreira RLT, Abrahao O, et al. Conformational preferences of non-nucleoside HIV-1 reverse transcriptase inhibitors [ J ]. Tetrahedron, 2001,57:3243 - 3253.
  • 9Barreca ML, Carotti A, Carrieri A, et al. Comparative molecular field analysis (CoMFA) and docking studies of non-nucleoside HIV-1 RT inhibitors (NNIs) [ J]. Bioorg Med Chem, 1999,7:2283 -2292.
  • 10Kalyan D, Ding JP, Yu H, et al. Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the tyr181cys HIV-1 RT drug-resistant mutant [J]. J Mol Biol, 1996,264:1085- 1100.

共引文献70

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部